Not applicableStudy completedNCT01446185What this trial is testingTreatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer PatientsWho this might be right forBreast Cancer Genomic Health®, Inc. 100
Testing effectiveness (Phase 2)UnknownNCT05469750What this trial is testingDalpiciclib Plus Letrozole and CapecitabineWho this might be right forAdvanced Breast Cancer Fujian Medical University Union Hospital 48
Large-scale testing (Phase 3)Not Yet RecruitingNCT07784036What this trial is testingJYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast CancerWho this might be right forBreast Cancer Chengdu JOYO pharma Co., Ltd. 171
Not applicableUnknownNCT04852081What this trial is testingAnalysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Who this might be right forBreast Cancer Stage IV Blokhin's Russian Cancer Research Center 1,000
Not applicableLooking for participantsNCT06106477What this trial is testingImpact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer Medical College of Wisconsin 20
Testing effectiveness (Phase 2)Looking for participantsNCT07616427What this trial is testingFovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerWho this might be right forHR+/HER2+ Early Breast Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine 100
Not applicableLooking for participantsNCT07379918What this trial is testingReal-life Evaluation of Endopredict® in Early HR+/HER2- Breast CancerWho this might be right forBreast Cancer (Early Breast Cancer)Breast Cancer SurvivorsBreast Cancer Prognostic+2 more Assistance Publique - Hôpitaux de Paris 1,000
Not applicableStudy completedNCT04992156What this trial is testingPrediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ETWho this might be right forMetastatic Breast Cancer Fudan University 50
Testing effectiveness (Phase 2)UnknownNCT05574881What this trial is testingDalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerWho this might be right forBreast Cancer Fudan University 72
Large-scale testing (Phase 3)Looking for participantsNCT06383767What this trial is testingA Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast CancerWho this might be right forMetastatic Breast Cancer Qilu Pharmaceutical Co., Ltd. 378
Large-scale testing (Phase 3)Looking for participantsNCT06058377What this trial is testingAdding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerWho this might be right forAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast Carcinoma+1 more National Cancer Institute (NCI) 3,680
Large-scale testing (Phase 3)Active Not RecruitingNCT05257395What this trial is testingXZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Xuanzhu Biopharmaceutical Co., Ltd. 397
Not applicableLooking for participantsNCT06033287What this trial is testingReal-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.Who this might be right forBreast CancerEndocrine TherapyCDK4/6 Inhibitors+1 more Hunan Cancer Hospital 300
Not applicableLooking for participantsNCT07084558What this trial is testingABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine ResponsivenessWho this might be right forEarly and Locally Advanced Breast Cancer Austrian Breast & Colorectal Cancer Study Group 350
Not applicableStudy completedNCT04394247What this trial is testingPatient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination TherapyWho this might be right forBreast Cancer Pfizer 242
Testing effectiveness (Phase 2)Active Not RecruitingNCT07130643What this trial is testingEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast CancerWho this might be right forHR+/HER2- Breast Cancer Xinhong Wu, PhD 40
Testing effectiveness (Phase 2)Looking for participantsNCT06726148What this trial is testingStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsWho this might be right forAdvanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small Cell Lung Cancer Novartis Pharmaceuticals 280
Large-scale testing (Phase 3)Study completedNCT02941926What this trial is testingStudy to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCWho this might be right forBreast Cancer Novartis Pharmaceuticals 3,246
Testing effectiveness (Phase 2)Active Not RecruitingNCT06702618What this trial is testingEvaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerWho this might be right forBreast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Large-scale testing (Phase 3)Ended earlyNCT05128773What this trial is testingStudy of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityWho this might be right forBreast Cancer Sanofi 3